Sarepta Therapeutics reports non-GAAP net loss of $29.1 million for Q4 2013
Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today reported financial results for the three months and year ended December 31, 2013, and provided an update of recent corporate developments. …read more
